DE60127901T2 - TCF-1 Nukleotidsequenzvariation - Google Patents
TCF-1 Nukleotidsequenzvariation Download PDFInfo
- Publication number
- DE60127901T2 DE60127901T2 DE60127901T DE60127901T DE60127901T2 DE 60127901 T2 DE60127901 T2 DE 60127901T2 DE 60127901 T DE60127901 T DE 60127901T DE 60127901 T DE60127901 T DE 60127901T DE 60127901 T2 DE60127901 T2 DE 60127901T2
- Authority
- DE
- Germany
- Prior art keywords
- allele
- tcf
- seq
- alleles
- genotype
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 title claims abstract description 132
- 125000003729 nucleotide group Chemical group 0.000 title claims description 61
- 239000002773 nucleotide Substances 0.000 title claims description 57
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 78
- 201000010099 disease Diseases 0.000 claims abstract description 42
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
- 206010003645 Atopy Diseases 0.000 claims abstract description 35
- 208000006673 asthma Diseases 0.000 claims abstract description 35
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 12
- 201000009961 allergic asthma Diseases 0.000 claims abstract 2
- 108700028369 Alleles Proteins 0.000 claims description 281
- 239000000523 sample Substances 0.000 claims description 132
- 230000000295 complement effect Effects 0.000 claims description 41
- 108091034117 Oligonucleotide Proteins 0.000 claims description 37
- 230000001404 mediated effect Effects 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 6
- 239000002751 oligonucleotide probe Substances 0.000 claims description 6
- 238000012512 characterization method Methods 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 21
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 12
- 102100030627 Transcription factor 7 Human genes 0.000 description 102
- 238000009396 hybridization Methods 0.000 description 76
- 238000003199 nucleic acid amplification method Methods 0.000 description 74
- 230000003321 amplification Effects 0.000 description 73
- 230000005540 biological transmission Effects 0.000 description 51
- 238000012360 testing method Methods 0.000 description 46
- 230000000694 effects Effects 0.000 description 40
- 150000007523 nucleic acids Chemical group 0.000 description 40
- 238000003205 genotyping method Methods 0.000 description 32
- 102000039446 nucleic acids Human genes 0.000 description 32
- 108020004707 nucleic acids Proteins 0.000 description 32
- 239000000047 product Substances 0.000 description 31
- 238000012546 transfer Methods 0.000 description 31
- 238000001514 detection method Methods 0.000 description 28
- 230000004044 response Effects 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 26
- 230000002068 genetic effect Effects 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 22
- 238000003752 polymerase chain reaction Methods 0.000 description 20
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 14
- 238000009826 distribution Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000013566 allergen Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000004069 differentiation Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 description 10
- 102100038823 RNA-binding protein 45 Human genes 0.000 description 10
- 208000027866 inflammatory disease Diseases 0.000 description 10
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 102000054766 genetic haplotypes Human genes 0.000 description 9
- 230000008774 maternal effect Effects 0.000 description 9
- 239000004677 Nylon Substances 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229920001778 nylon Polymers 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000000585 Mann–Whitney U test Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000008775 paternal effect Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 206010047924 Wheezing Diseases 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 6
- 230000001364 causal effect Effects 0.000 description 6
- 230000024245 cell differentiation Effects 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 5
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 5
- 210000004241 Th2 cell Anatomy 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000001502 gel electrophoresis Methods 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 208000037656 Respiratory Sounds Diseases 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229960004784 allergens Drugs 0.000 description 4
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 4
- 229960005542 ethidium bromide Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 4
- 229960002329 methacholine Drugs 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 238000012353 t test Methods 0.000 description 4
- 230000006820 DNA synthesis Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010074338 Lymphokines Proteins 0.000 description 3
- 102000008072 Lymphokines Human genes 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229940046528 grass pollen Drugs 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000037230 mobility Effects 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- -1 nucleoside triphosphates Chemical class 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000000405 serological effect Effects 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 108010068698 spleen exonuclease Proteins 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 235000011178 triphosphate Nutrition 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000447 Th1 cell Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000036427 bronchial hyperreactivity Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000012146 running buffer Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- UCDLBNQQNRQANR-UHFFFAOYSA-N 4-(4-amino-3-methylphenyl)-2,6,6-trimethylcyclohexa-2,4-dien-1-amine Chemical compound CC1(C)C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 UCDLBNQQNRQANR-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 229930182474 N-glycoside Natural products 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 238000012952 Resampling Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108050005484 Transcription factor 7 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 101000988661 Xenopus laevis Hepatocyte nuclear factor 1-alpha-A Proteins 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000012093 association test Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000588 effect on asthma Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000003783 haploid cell Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000003351 stiffener Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000005451 thionucleotide Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 201000006382 tuberculoid leprosy Diseases 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21981200P | 2000-07-21 | 2000-07-21 | |
| US219812 | 2000-07-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60127901D1 DE60127901D1 (de) | 2007-05-31 |
| DE60127901T2 true DE60127901T2 (de) | 2008-01-17 |
Family
ID=22820882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60127901T Expired - Lifetime DE60127901T2 (de) | 2000-07-21 | 2001-07-17 | TCF-1 Nukleotidsequenzvariation |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6656691B2 (enExample) |
| EP (1) | EP1174522B1 (enExample) |
| JP (1) | JP4846130B2 (enExample) |
| AT (1) | ATE360094T1 (enExample) |
| DE (1) | DE60127901T2 (enExample) |
| ES (1) | ES2286060T3 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100559182C (zh) | 2003-08-29 | 2009-11-11 | 株式会社东芝 | 显色试剂、浓度测定试剂盒、浓度测定方法和在该方法中使用的传感器芯片 |
| EP1802758A4 (en) * | 2004-10-01 | 2008-08-27 | Temasek Life Sciences Lab Ltd | ORYZA SATIVA LECTINE TYPE 1 RECEPTOR KINASE (OSLRK1), GENE INVOLVED IN PLANT DEVELOPMENT |
| US20080268442A1 (en) * | 2007-04-24 | 2008-10-30 | Igd Intel, Llc | Method and system for preparing a blood sample for a disease association gene transcript test |
| US20090125244A1 (en) * | 2007-11-09 | 2009-05-14 | Igd Intel Llc | Broad-based neurotoxin-related gene mutation association from a gene transcript test |
| US8135545B2 (en) | 2007-11-09 | 2012-03-13 | Iverson Genetic Diagnostics, Inc. | System and method for collecting data regarding broad-based neurotoxin-related gene mutation association |
-
2001
- 2001-07-12 US US09/904,420 patent/US6656691B2/en not_active Expired - Fee Related
- 2001-07-17 AT AT01116692T patent/ATE360094T1/de active
- 2001-07-17 DE DE60127901T patent/DE60127901T2/de not_active Expired - Lifetime
- 2001-07-17 EP EP01116692A patent/EP1174522B1/en not_active Expired - Lifetime
- 2001-07-17 ES ES01116692T patent/ES2286060T3/es not_active Expired - Lifetime
- 2001-07-19 JP JP2001220567A patent/JP4846130B2/ja not_active Expired - Fee Related
-
2003
- 2003-06-04 US US10/455,058 patent/US20030203395A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1174522B1 (en) | 2007-04-18 |
| JP4846130B2 (ja) | 2011-12-28 |
| EP1174522A3 (en) | 2004-02-18 |
| DE60127901D1 (de) | 2007-05-31 |
| EP1174522A9 (en) | 2002-07-03 |
| JP2002330755A (ja) | 2002-11-19 |
| US6656691B2 (en) | 2003-12-02 |
| ES2286060T3 (es) | 2007-12-01 |
| US20030054350A1 (en) | 2003-03-20 |
| ATE360094T1 (de) | 2007-05-15 |
| US20030203395A1 (en) | 2003-10-30 |
| EP1174522A2 (en) | 2002-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68926784T2 (de) | Verfahren zur charakterisierung von hla dp | |
| Iyengar et al. | Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration | |
| CN101796197B (zh) | 预测抗tnf响应性或无响应性的生物标志物 | |
| DE69838984T2 (de) | Risikoabschätzung für chronische atemwegserkrankungen und anwendungen | |
| DE69616478T2 (de) | Nachweis genetischer Prädisposition zu periodontalen Erkrankungen | |
| Fitness et al. | Large-scale candidate gene study of leprosy susceptibility in the Karonga district of northern Malawi. | |
| DE69715669T2 (de) | Detektion einer genetischen prädisposition für diabetische retinopathie mit dem risiko des verlusts der sehkraft | |
| DE69231595T2 (de) | Bestimmung von mutationen im zusammenhang mit dem digeorge-syndrom | |
| DE69003477T2 (de) | Verfahren zum Nachweis von Nucleinsäuren. | |
| Chiu et al. | Glucokinase gene in gestational diabetes mellitus: population association study and molecular scanning | |
| DE69523586T2 (de) | Verfahren zum screening für die erkrankung crohn durch die verwendung von tnf-mikrosatelliten allelen | |
| DE60026150T2 (de) | Diagnostika und therapeutika für osteoporose | |
| DE69230221T2 (de) | Verfahren für die in-vitro-diagnose von mit charcot-marie-tooth-krankheit vom typ-1a zusammenhängenden chromosomenanomalien | |
| DE69503885T2 (de) | Gemeinschaftlich verwendete genetische marker zur diagnostik der alzheimerschen krankheit, methode und diagnostischer reagenziensatz | |
| EP1730315B1 (de) | Polymorphismen im nod2/card15 gen | |
| DE69125368T2 (de) | Karakterisierung von hla-dqbeta-dns | |
| DE60127901T2 (de) | TCF-1 Nukleotidsequenzvariation | |
| DE69506704T2 (de) | Verfahren und proben zum nachweis von mit dem locus der infantilen spinalamyotrophien verbundenen markern | |
| DE60036750T2 (de) | Verfahren zur Abschätzung der Sensitivität für Osteoporose-Medikamente | |
| DE60226244T2 (de) | Il-4 rezeptor sequenzvarianten, die mit typ i diabetes assoziiert sind | |
| DE602004009083T2 (de) | Verwendung von humanen oatp-c polymorphismen, die einen effekt auf die pharmakokinetik von statin haben, bei der statin-therapie | |
| DE69120526T2 (de) | Allelische verbindung des humanen dopamin-(d2)rezeptor-gens in kompulsionsstörungen wie alkoholismus | |
| DE69734904T2 (de) | ABO-Glycosyltransferase-Sequenz-Polymorphismus | |
| EP1390531B1 (de) | Quantitative diagnostische analyse der prädisposition für hypertonie | |
| DE602005004026T2 (de) | Einen transkriptionsfaktor kodierendes humanes prädispositionsgen für autismus sowie dessen verwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |